References
  1. CMS Manual System. Pub 100-03 Medicare National Coverage Determinations. National Coverage Determination (NCD20.8.4): Leadless Pacemakers. Department of Health & Human Services, Centers for Medicare & Medicaid Services.
  2. Piccini JP, El-Chami M, Wherry K, Crossley GH, Kowal RC, Stromberg K, Longacre C, Hinnenthal J, Bockstedt L. Contemporaneous Comparison of Outcomes Among Patients Implanted With a Leadless vs Transvenous Single-Chamber Ventricular Pacemaker. JAMA Cardiol. 2021;6(10):1187-1195. doi:10.1001/jamacardio.2021.2621
  3. El-Chami M, Bockstedt L, Longacre C, Higuera L, Stromberg K, Crossley G, Kowal RC, Piccini JP. Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED Study: 2-year follow-up. European Heart Journal 2022; 43: 1207-1215. https://doi.org/10.1093/eurheartj/ehab767.
  4. Duray GZ, Ritter P, El-Chami M et al.; Micra Transcatheter Pacing Study Group. Long-term performance of a transcatheter pacing system: 12-month results from the Micra transcatheter pacing study. Heart Rhythm 2017;14:702–709.
  5. El-Chami MF, Al-Samadi F, Clementy N et al. Updated performance of the Micra transcatheter pacemaker in the real-world setting: a comparison to the investigational study and a transvenous historical control. Heart Rhythm 2018;15: 1800–1807.
  6. Wherry K, Stromberg K, Hinnenthal JA, Wallenfelsz LA, El-Chami MF, Bockstedt L. Using Medicare Claims to Identify Acute Clinical Events Following Implantation of Leadless Pacemakers. Pragmat Obs Res 2020;11:19-26.
  7. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
  8. Anker SD, Schroeder S, Atar D et al. Traditional and new composite endpoints in heart failure clinical rials: facilitating comprehensive efficacy assessments and improvement trial efficiency. European Journal of Heart Failure 2016; 18(5): 482-489.
  9. Li F, Thomas LE, Li F. Addressing extreme propensity scores via the overlap weights. Am J Epidemiol 2019;188:250–257.
  10. Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc 2018;113:390–400.
  11. Kucharska-Newton AM, Heiss G, Ni H et al. Identification of heart failure events in Medicare claims: the Atherosclerosis Risk in Communities (ARIC) study. J Card Fail 2016;22:48–55.
  12. Sanchez R, Nadkarni A, Buck B et al. Incidence of pacing-induced cardiomyopathy in pacemaker-dependent patients is lower with leadless pacemakers compared to transvenous pacemakers. J Cardiovasc Electrophysiol 2021; 32:477-483.
  13. Wilkoff BL, Boriani G, Mittal S et al. Impact of Cardiac Implantable Electronic Device Infection: A Clinical and Econonic Analysis of the WRAP-IT Trial. Circulation AE 2020; 13(5). https://doi.org/10.1161/CIRCEP.119.008280.
  14. El-Chami M, Piccini JP, Bockstedt L. In Reply: Leadless Pacing – Uncertainties Remain About Safety and Efficacy. JAMA Cardiology. Published Online: January 26, 2022. doi:10.1001/jamacardio.2021.5713.